Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.
Reads0
Chats0
TLDR
The potential of MSCs as a therapeutic option for patients with CO VID-19 is discussed, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease.Abstract:
The COVID-19 pandemic has led to a major setback in both the health and economic sectors across the globe. The scale of the problem is enormous because we still do not have any specific anti-SARS-CoV-2 antiviral agent or vaccine. The human immune system has never been exposed to this novel virus, so the viral interactions with the human immune system are completely naive. New approaches are being studied at various levels, including animal in vitro models and human-based studies, to contain the COVID-19 pandemic as soon as possible. Many drugs are being tested for repurposing, but so far only remdesivir has shown some positive benefits based on preliminary reports, but these results also need further confirmation via ongoing trials. Otherwise, no other agents have shown an impactful response against COVID-19. Recently, research exploring the therapeutic application of mesenchymal stem cells (MSCs) in critically ill patients suffering from COVID-19 has gained momentum. The patients belonging to this subset are most likely beyond the point where they could benefit from an antiviral therapy because most of their illness at this stage of disease is driven by inflammatory (over)response of the immune system. In this review, we discuss the potential of MSCs as a therapeutic option for patients with COVID-19, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease.read more
Citations
More filters
Journal ArticleDOI
Role of Toll-like receptors in the pathogenesis of COVID-19.
Journal ArticleDOI
Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era.
Ángel Serrano-Aroca,Kazuo Takayama,Alberto Tuñón-Molina,Murat Seyran,Sk. Sarif Hassan,Pabitra Pal Choudhury,Vladimir N. Uversky,Kenneth Lundstrom,Parise Adadi,Giorgio Palù,Alaa A. A. Aljabali,Gaurav Chauhan,Ramesh Kandimalla,Murtaza M. Tambuwala,Amos Lal,Tarek Mohamed Abd El-Aziz,Tarek Mohamed Abd El-Aziz,Samendra P. Sherchan,Debmalya Barh,Elrashdy M. Redwan,Nicolas G. Bazan,Yogendra Kumar Mishra,Bruce D. Uhal,Adam Brufsky +23 more
TL;DR: In this article, the authors evaluated the antiviral activity and broad-spectrum antimicrobial properties of carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives.
Journal ArticleDOI
Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey.
Yu Hashimoto,Hidenori Ogata,Ryo Yamasaki,Takakazu Sasaguri,Senri Ko,Ken Ichiro Yamashita,Zhang Xu,Takuya Matsushita,Takahisa Tateishi,Shinichi Akiyama,Shoichi Maruyama,Akifumi Yamamoto,Jun Ichi Kira +12 more
TL;DR: CIDP with MN and anti-CNTN1 antibody-positive CIDP show considerable overlap but are not identical, probably heterogeneous and some cases harbor anti- cntN1 antibodies.
Journal ArticleDOI
Nanotheranostics against COVID-19: From multivalent to immune-targeted materials.
TL;DR: Besides the inactivation or destruction of the virus, functionalized nanoparticles capable of modulating patient’s immune response might be of great significance for attenuating the exaggerated inflammatory reactions or development of the effective nanovaccines and medications against the virus pandemics including the COVID-19.
Journal ArticleDOI
The tissue proteome in the multi-omic landscape of kidney disease.
TL;DR: The authors discuss proteomics research findings in nephrology and the potential, as well as the limitations, of using proteomics techniques to uncover disease mechanisms and develop new therapeutic strategies.
References
More filters
Journal ArticleDOI
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI
A new coronavirus associated with human respiratory disease in China.
Fan Wu,Su Zhao,Bin Yu,Yan-Mei Chen,Wen Wang,Zhi gang Song,Yi Hu,Zhao Wu Tao,Jun Hua Tian,Yuan Yuan Pei,Ming Li Yuan,Yu Ling Zhang,Fa Hui Dai,Yi Liu,Qi Min Wang,Jiao Jiao Zheng,Lin Xu,Edward C. Holmes,Edward C. Holmes,Yong-Zhen Zhang,Yong-Zhen Zhang +20 more
TL;DR: Phylogenetic and metagenomic analyses of the complete viral genome of a new coronavirus from the family Coronaviridae reveal that the virus is closely related to a group of SARS-like coronaviruses found in bats in China.
Journal ArticleDOI
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Xiaobo Yang,Yuan Yu,Jiqian Xu,Huaqing Shu,Jia'an Xia,Hong Liu,Hong Liu,Yongran Wu,Lu Zhang,Zhui Yu,Minghao Fang,Ting Yu,Yaxin Wang,Shangwen Pan,Xiaojing Zou,Shiying Yuan,You Shang,You Shang +17 more
TL;DR: The clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital between late December, 2019 and Jan 26, 2020 are described.
Journal ArticleDOI
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
TL;DR: ACE2 is abundantly present in humans in the epithelia of the lung and small intestine, which might provide possible routes of entry for the SARS‐CoV.
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.